The US FDA has scheduled a Psychopharmacologic Drugs Advisory Committee (PDAC) meeting for Thursday, February 16, 2017. The Committee will discuss new drug application (NDA) 209241, submitted by Neurocrine Biosciences, Inc. (Neurocrine), regarding Valbenazine 40 mg capsules, for the proposed treatment of Tardive Dyskinesia.
See the SAC Tracker report